Amgen Slides After BMO Downgrade and Rival Heart-Drug Miss
BMO cut Amgen to Market Perform on valuation after a 34% YTD rally. A Novartis Lp(a) trial miss also raises questions for Amgen’s olpasiran.
/ 1648 items
#XY↓
Novartis, Ionis Heart Drug Misses Phase 3 Goal Despite Cutting Lp(a)
Novartis and Ionis said pelacarsen lowered Lp(a) but failed to cut heart attacks, strokes or deaths in a Phase 3 trial of 8,323 patients.
Canaccord Initiates Belite Bio at Buy With $303 Target on Stargardt Therapy
Canaccord cites tinlarebant as the first drug shown to slow Stargardt lesion growth. The PDUFA date is February 12, 2027.
BTIG Starts Coverage on Tiziana With Buy Rating as Key MS Trial Nears
Nasal foralumab aims to cut brain inflammation in SPMS and MSA ahead of October INFORM-MS data.
HUTCHMED and GSK Sign Deal for Dual-Targeted KRAS-EGFR Cancer Drug
HUTCHMED licenses HMPL-A830, a KRAS-EGFR ATTC, to GSK for $110M upfront. Trials start H2 2026 in colorectal, pancreatic and lung cancers.
Ultragenyx Stock Plunges After Phase 3 Failure in Angelman Syndrome
GTX-102 failed Phase 3 in Angelman syndrome. Ultragenyx will review the program and reduce expenses.